Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 3

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Lymphoid 1

Conditions

Astrocytoma 2Lymphoma, Follicular 1Glioma 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Interventional × vorasidenib × Clear all
NCT06809322 2026-05-22

VIGOR

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Recruiting
468 enrolled
CNS

Astrocytoma

NCT07215910 2025-10-14

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Alliance for Clinical Trials in Oncology

Phase 3 Not yet recruiting
408 enrolled
CNSLymphoid

Astrocytoma, Lymphoma, Follicular

NCT04164901 2025-04-03

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Servier

Phase 3 Active not recruiting
331 enrolled 25 charts 1 FDA
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡